The Middle East and Turkey hemophilia treatment market is expected to expand significantly, owing to market players’ increasing adoption of partnership and acquisition strategies, as well as rising government and market sector initiatives to provide cost-effective hemophilia care. In February 2019, F. Hoffmann-La Roche AG donated Hemlibra to 1,000 hemophilia A patients in developing countries as part of the World Federation of Hemophilia (WFH) Humanitarian Aid Program
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3250
Several major competitors are concentrating their efforts on getting their novel products approved and introducing them into the market. The approval and introduction of such innovative products in the market is expected to create a favorable climate for the Middle East and Turkey hemophilia treatment market to expand over the forecast period. The European Commission granted Novo Nordisk marketing authorization for Esperoct in Europe in June 2019. Turoctocog alfa pegol, N8-GP, is a brand name for turoctocog alfa pegol, a drug used to treat hemophilia A in children and adults (congenital factor VIII deficiency) In April 2019, Roche Products India Pvt Ltd unveiled emicizumab, a hemophilia A medication marketed in India as Hemlibra. Via Factor VIII inhibitors, it is suggested as a prophylactic therapy for reducing the incidence of bleeding episodes in patients with hemophilia A.
Key players are concentrating their efforts on the advancement of new drug delivery therapies for the treatment of hemophilia, which is supposed to provide a lucrative opportunity for them to have advanced drug delivery systems. Researchers from The University of Texas at Austin’s Cockrell School of Engineering created a biodegradable delivery device called A capsule for people with Factor VIII deficiency in 2016. It includes micro and nanoparticles that hold a hemophilia protein treatment.
Due to increased product releases for treating hemophilia by key players, the Middle East and Turkey hemophilia treatment market is projected to develop at a CAGR of 4.2 percent during the forecast period (2019-2027). HEMLIBRA, an anti-coagulation factor IXa/X humanized bio-specific monoclonal antibody/coagulation factor VIII replacement, was introduced in May 2018 by Chugai Pharmaceutical Co., Ltd., a Roche Group subsidiary, to eliminate or decrease the risk of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) who are taking factor VIII inhibitors.
Over the forecast period, the Middle East and Turkey hemophilia treatment market is expected to expand due to an increase in clinical trials by key players. At the 12th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD) in Prague, Czech Republic, Takeda Pharmaceutical Company Limited presented findings from its phase IIIb/IV clinical trial for ADYNOVATE, a recombinant anti-hemophilic factor.
Major companies contributing in the Middle East and Turkey hemophilia treatment market are Baxter International Inc., Bayer AG, Octapharma AG, Ferring B.V., Sanofi S.A., Novo Nordisk A/S, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Spark Therapeutics, Inc., Grifols S.A., Kedrion, Pfizer, Inc., Swedish Orphan Biovitrum AB, CSL Behring, and Biogen Inc.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/3250
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Middle East and Turkey Hemophilia Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Middle East and Turkey Hemophilia Treatment Industry Impact
Chapter 2 Middle East and Turkey Hemophilia Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Middle East and Turkey Hemophilia Treatment (Volume and Value) by Type
2.3 Middle East and Turkey Hemophilia Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Middle East and Turkey Hemophilia Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 Company Profiles and Key Figures in Middle East and Turkey Hemophilia Treatment Business
Chapter 6 Middle East and Turkey Hemophilia Treatment Market Forecast (2022-2028)
Chapter 7 Conclusions
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/3250
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027